• Smile Brands Scoops Up Dentistry of Sarasota

    On December 2, Smile Brands, one of the largest providers of dental support services in the United States, announced its new partnership with Dentistry of Sarasota. Financial terms of the deal were not disclosed. Smile Brands provides business support services to general and multi-specialty dental groups since its founding in 1998. The company... Read More »
  • Ingenovis Health to Acquire HealthCare Support

    Ingenovis Health, Inc., one of the fastest-growing providers of healthcare staffing, announced on November 29 that it has agreed to acquire HealthCare Support, a national healthcare staffing platform providing a full range of customized hiring solutions across the country. Financial terms of the transaction, which is expected to close in the... Read More »
  • Edifecs to Acquire Health Fidelity

    On November 22, Edifecs, Inc. announced that it has signed a definitive agreement to acquire Health Fidelity, a leading provider of risk adjustment solutions for the value-based care era. The acquisition is expected to close in mid-December of this year, pending regulatory approval. Founded in 1996, Edifecs is a premier technology company in the... Read More »
  • Israeli Startup TailorMed Acquires Vivor

    On November 29, TailorMed, a leading financial navigation platform that helps healthcare organizations and patients remove financial barriers to care, announced that it has acquired Vivor, a financial assistance technology platform for healthcare providers and life sciences. The financial terms of the transaction were not disclosed. TailorMed is... Read More »
  • HomeCentris Healthcare Acquires Grace Home Healthcare

    On November 26, HomeCentris Healthcare, LLC announced that it had acquired Grace Home Healthcare, LLC. The deal was closed in October for an undisclosed amount. Headquartered in Owings Mills, Maryland, HomeCentris Healthcare, LLC is an independent home and community-based care organization. It was founded in 2000 and provides its services to... Read More »
CRO M&A Market in 2020 (So Far)

CRO M&A Market in 2020 (So Far)

There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For 2020, only 10% of deals in the Other Services sector have targeted a CRO company (14 deals). To put that in context, CROs were targeted in 15% (29 transactions) of deals in the Other Services sector for 2019, according to The 2020 Health Care Services Acquisition Report. There haven’t been many headline deals this year for the CRO market.... Read More »
Catalent acquires MaSTherCell Global

Catalent acquires MaSTherCell Global

Catalent, Inc. (NYSE: CTLT) announced a $315 million deal for MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization based in Gosselies, Belgium. It is backed by Great Point Partners, SFPI-FPIM (the Belgian Federal Holdings and Investment Company) and Orgenesis Inc. (NASDAQ: ORGS). This is the Somerset, New Jersey-based CRO’s fifth deal since 2014, all of them for domestic targets, according to search results in our Healthcare Deals Database. Its most recent one was announced in April 2019, for Baltimore-based Paragon Bioservices, Inc., a contract research organization, for $1.2 billion. Founded in 2011, MaSTherCell has a... Read More »
PE Firms Trade WIRB-Copernicus for $3 Billion

PE Firms Trade WIRB-Copernicus for $3 Billion

Leonard Green & Partners, L.P won the auction to acquire WIRB-Copernicus Group (WCG) from Arsenal Capital Partners for $3 billion. The purchase value was originally reported in PE Hub Buyouts. WCG is a clinical services organization that enables biopharmaceutical companies, contract research organizations and institutions to accelerate the delivery of new treatments and therapies to patients. Arsenal will retain a stake in WCG. It acquired the company in March 2012 and led its recapitalization in August 2016 alongside other investors, including MSD Partners, the family office of Michael Dell. WCG has an estimated EBITDA of $175 million for 2019. WCG has been relatively quiet on the... Read More »
CROs Are Still Trending as Q4 Rolls On

CROs Are Still Trending as Q4 Rolls On

In the first week of November, BioAgilytix Labs, LLC, a portfolio company of Riverside Partners, purchased Cambridge Biomedical. Both Cambridge and BioAgilytix are contract research organizations (CROs) that develop novel therapeutic biologics and biosimilars, specializing in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany. It also gives BioAgilytix a total of 400 employees. The merger follows a busy October for CROs, in which five deals were reported, accounting for... Read More »
CROs and CDMOs are Still Selling Fast

CROs and CDMOs are Still Selling Fast

This past week Permira, a global investment firm based in the United Kingdom, spent $2.4 billion for Cambrex Corporation (NYSE: CBM). Cambrex is a premier contract development and manufacturing organization (CDMO) in the small molecule space and provides drug substance, drug product and analytical services across the entire drug lifecycle. The $2.4 billion purchase price includes the company’s net debt, for 4.2x revenue and 16.3x EBITDA,  represents a 47.1% premium to Cambrex’s closing price of $40.78 on August 6. The target reported a number of its own acquisitions recently, making the CDMO a more attractive buy. Cambrex acquired Halo Pharma in 2018 and Avista Pharma Solutions... Read More »
CROs Are Still Trending as Q4 Rolls On

Will Catalent’s Deal Launch the Next Wave of CRO M&A?

Contract research organizations (CROs), like contract development and manufacturing organizations (CDMOs), have been popular targets for private equity firms and strategic buyers for years. The deals seem to come in waves, and the healthcare M&A market may be in for a tsunami this year. In 2013, some 20 transactions for CRO/CDMO targets were announced, with some hefty price tags attached. Royal DSM paid $1.95 billion to buy Patheon. Other big deals that didn’t disclose prices came from KKR & Co. (NYSE: KKR), which acquired both PRA International and ReSearch Pharmaceutical Services that year. CRO deal volume rose a little in 2014 (27 deals), then ebbed in 2015 (11 deals). The... Read More »